What type of drug does Alpelisib belong to? Is it a targeted drug?

Alpelisib (Alpelisib) is an anti-cancer drug classified as a targeted therapy drug. It mainly acts on the PI3K (phosphatidylinositol 3-kinase) signaling pathway. This pathway is overactivated in a variety of cancers, and is especially common in breast cancer patients carrying PIK3CA gene mutations. Apelvis selectively inhibits PI3Kα isoform, thereby blocking the growth and proliferation signals of tumor cells and achieving the effect of inhibiting tumor development. Therefore, it is classified as a precision targeted drug.

In clinical practice, Apelvis is commonly used to treat HR-positive, HER2-negative and PIK3CA mutated advanced breast cancer. It is usually used in combination with the endocrine therapy drug fulvestrant. The use of this drug has been proven through multiple clinical trials to have a significant effect on delaying disease progression, and is especially suitable for patients with endocrine resistance. Its targeted effect makes treatment more personalized and is different from traditional chemotherapy's extensive killing of normal cells.

It is worth noting that although apelvis is a targeted drug, its use is also accompanied by some common side effects, including hyperglycemia, rash, diarrhea, etc. Some patients even need to adjust the dose or discontinue treatment due to adverse reactions. Therefore, it is necessary to closely monitor blood sugar levels and skin conditions during medication, and handle side effects in a timely manner under the guidance of a doctor to ensure smooth treatment.

To sum up, Apelvis is a targeted drug that specifically targets specific gene mutations (PIK3CAmutation). Its advent provides a new treatment option for breast cancer patients, especially the endocrine-resistant group. Compared with traditional treatments, it has significant advantages in accuracy and efficacy, but patients need to undergo genetic testing before use and use drugs rationally under the guidance of professional doctors.

Reference materials:https://www.drugs.com